Vek­lury per­forms bet­ter the soon­er it's giv­en, Gilead says in new study and re­al-world analy­sis

While some stud­ies and analy­ses have claimed that Vek­lury is in­ef­fec­tive for treat­ing Covid-19, Gilead is fir­ing back — and this time, it has some da­ta it wants to show for its drug, which made more than $5 bil­lion last year and has a $3,000 price tag.

Gilead re­leased da­ta from sev­er­al stud­ies/analy­ses on Sun­day at a con­fer­ence in Por­tu­gal, tak­ing a look at the num­ber of pa­tients on Vek­lury and its ef­fect on hos­pi­tal­iza­tions. One analy­sis showed that more than 50% of pa­tients hos­pi­tal­ized with Covid-19 were on Vek­lury, most­ly giv­en in com­bi­na­tion with oth­er un­named ther­a­pies. More da­ta from the Phase III PINE­TREE study showed that over­all, use of Vek­lury with­in ei­ther five days of symp­tom on­set, or be­tween 5 to 7 days of symp­tom on­set, re­duced hos­pi­tal­iza­tions in pa­tients at high risk for se­vere Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER